Article citationsMore>>

Clackson, T., Metcalf, C.A., Rivera, V.M., Knowles, H.L., Tang, H. and Burns, K.D. (2003) Broad anti-tumor activity of ap23573, an mTOR inhibitor in clinical development. American Society of Clinical Oncology, 22, 882.

has been cited by the following article:

• TITLE: Effect of deforolimus and VEGF on angiogenesis in endometrial stromal cells following three-dimensional culture

  AUTHORS: Jafar Ai, Somayeh Ebrahimi, Armin Ai, Roya Karimi, Naghmeh Bahrami

  KEYWORDS: Endometrial Stromal Cells; Endometrium; 3-D culture; Deforolimus; VEGF

  JOURNAL NAME: Stem Cell Discovery, Vol.3 No.1, January 11, 2013

  ABSTRACT: The presence of endometrial tissue outside of the uterine cavity is named endometriosis and is the most common gynecologic disorder in women. Determining the inhibitory effect of a Deforolimus on angiogenesis in a three-dimensional (3-D) culture of human endometrial stromal cells (hEnCs) in vitro. The important mechanism in the pathogenesis of endometriosis is angiogenesis, and deforolimus has been shown to have anti-angiogenic activity. This was an in vitro study of human endometrial stromal cells in 3-D culture of fibrin matrix. Endometrial stromal cells isolated and placed in a 3-D fibrin matrix culture system for angiogenesis with VEGF and inhibit angiogenesis by deforolimus. Finally these cells analyzed by CD31 antibodies. After 3 weeks, in cells treated with VEGF, endothelial cell branching was observed and rudimentary capillary-like structures formed. In the presence of 5μM of deforolimus, angiogenesis was reduced. The deforolimus were shown to be effective in inhibiting the mechanisms of angiogenesis.